Author

L. Bouche

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. Dell· 2 shared S. M. Haslam· 2 shared A. Antonopoulos· 1 shared A. Filer· 1 shared A. Kaghad· 1 shared A. Keller· 1 shared A. Khan· 1 shared A. Li· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

A. Dell

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Decreased fucosylation impacts epithelial integrity and increases risk for COPD.

C. Swaby, B. Yeung-Luk, S. Thapa, K. Nishida, A. Wally, B. Ghosh, A. Niederkofler, S. Luk, M. Girgis, A. Keller, C. Cortez, S. Ramaswamy, K. Wilmsen, L. Bouche, A. Dell, , V. K. Sidhaye

This study shows decreased fucosylation impairs epithelial integrity and increases COPD risk by affecting E-cadherin function and cell differentiation.

bioRxiv · Oct 31, 2023 · PreprintCell Biology

Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics

M. Sutherland, A. Li, A. Kaghad, D. Panagopoulos, F. Li, M. Szewczyk, D. Smil, C. Scholten, L. Bouche, T. Stellfeld, C. Arrowsmith, D. Barsyte, M. Vedadi, I. V. Hartung, H. Steuber, , V. Santhakumar

This study designs and synthesizes a new class of selective PRMT4 inhibitors with improved selectivity over other PRMT family members.

bioRxiv · Nov 17, 2020Pharmacology & Toxicology

Loss of α2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in Rheumatoid Arthritis.

Y. Wang, A. Khan, A. Antonopoulos, L. Bouche, C. D. Buckley, A. Filer, K. Raza, K. Ping-Li, B. Tolusso, E. Gremese, M. Kurowska-Stolarska, S. Alivernini, A. Dell, S. M. Haslam, M. A. Pineda

This study shows that reduced α2-6 sialylation in synovial fibroblasts contributes to a pro-inflammatory phenotype in RA by altering glycosylation pathways.

bioRxiv · Mar 8, 2020Immunology